Health Canada InfoWatch: New information regarding the risk of muscle-related disorders has been added to the Post-Market Adverse Drug Reactions and Consumer Information sections of the Canadian product monographs for Proscar and Propecia. Key messages for healthcare professionals: Rare cases of muscle-related disorders, such as rhabdomyolysis, myopathy, myalgia, myasthenia, and creatine kinase elevation, have been...
Discontinuation of Amaryl
Sanofi-aventis Canada announced in June, 2018 that it will immediately stop the distribution of Amaryl (Glimipiride) 1,2 and 4mg tabs in Canada. Glimepiride (original trade name Amaryl) is an orally available medium-to-long-acting Sulfonylurea antidiabetic drug.